TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:00
CODEXIS INC. ( CDXS ) https://www.codexis.com
3.45USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-10.85%
CDXS
SPY
32.74%
-83.33%
CDXS
SPY
92.93%
-83.20%
CDXS
SPY
224.41%
CDXS
71.64%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
243.97
201.22
0.34
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.99
3.30
2.82
-22.75
0.00
-4.47
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-345.59
75.76
-85.18
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
10.3126
-75.90
-84.91
1.62
Other Earnings and Cash Flow Stats:
CODEXIS INC. ( CDXS ) Net Income TTM ($MM) is -80.12
CODEXIS INC. ( CDXS ) Operating Income TTM ($MM) is -76.44
CODEXIS INC. ( CDXS ) Owners' Earnings Annual ($MM) is -27.82
CODEXIS INC. ( CDXS ) Current Price to Owners' Earnings ratio is -8.67
CODEXIS INC. ( CDXS ) EBITDA TTM ($MM) is -47.29
CODEXIS INC. ( CDXS ) EBITDA Margin is -85.18%
Capital Allocation:
CODEXIS INC. ( CDXS ) has paid 0.00 dividends per share and bought back -4.561 million shares in the past 12 months
CODEXIS INC. ( CDXS ) has reduced its debt by 29.642 million USD in the last 12 months
Capital Structure:
CODEXIS INC. ( CDXS ) Interest-bearing Debt ($MM) as of last quarter is 22
CODEXIS INC. ( CDXS ) Annual Working Capital Investments ($MM) are 6
CODEXIS INC. ( CDXS ) Book Value ($MM) as of last quarter is 86
CODEXIS INC. ( CDXS ) Debt/Capital as of last quarter is 25%
Other Balance Sheet Stats:
CODEXIS INC. ( CDXS ) has 65 million in cash on hand as of last quarter
CODEXIS INC. ( CDXS ) has 35 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CODEXIS INC. ( CDXS ) has 69 common shares outstanding as of last quarter
CODEXIS INC. ( CDXS ) has 0 million USD of preferred stock value
Academic Scores:
CODEXIS INC. ( CDXS ) Altman Z-Score is -3.70 as of last quarter
CODEXIS INC. ( CDXS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
CODEXIS INC. ( CDXS ) largest shareholder is Nantahala Capital Management, LLC owning 5069443 shares at 17.49 ($MM) value
Byron L Dorgan(an insider) Sold 20000 shares of CODEXIS INC. ( CDXS ) for the amount of $42200.00 on 2023-11-15
2.83% of CODEXIS INC. ( CDXS ) is held by insiders, and 92.46% is held by institutions
CODEXIS INC. ( CDXS ) went public on 2010-04-22
Other CODEXIS INC. ( CDXS ) financial metrics:
FCF:11.33
Unlevered Free Cash Flow:-48.70
EPS:-2.00
Operating Margin:-345.59
Gross Profit Margin:75.76
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-161.21
Beta:1.62
Buffet's Owners Earnings:-27.82
Price to Owner's Earnings:-8.67
About CODEXIS INC. ( CDXS ) :
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.